Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Pembrolizumab injection; Drug: Capecitabine tablets; Radiation: Local radiotherapy Sponsor: UNICANCER Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Condition: Locally Advanced Unresectable Gastric Adenocarcinoma Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cadonilimab Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Pembrolizumab injection; Drug: Capecitabine tablets; Radiation: Local radiotherapy Sponsor: UNICANCER Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Condition: Locally Advanced Unresectable Gastric Adenocarcinoma Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cadonilimab Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Pembrolizumab injection; Drug: Capecitabine tablets; Radiation: Local radiotherapy Sponsor: UNICANCER Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Condition: Locally Advanced Unresectable Gastric Adenocarcinoma Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cadonilimab Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Pembrolizumab injection; Drug: Capecitabine tablets; Radiation: Local radiotherapy Sponsor: UNICANCER Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Condition: Locally Advanced Unresectable Gastric Adenocarcinoma Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cadonilimab Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Pembrolizumab injection; Drug: Capecitabine tablets; Radiation: Local radiotherapy Sponsor: UNICANCER Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Condition: Locally Advanced Unresectable Gastric Adenocarcinoma Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cadonilimab Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Pembrolizumab injection; Drug: Capecitabine tablets; Radiation: Local radiotherapy Sponsor: UNICANCER Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Condition: Locally Advanced Unresectable Gastric Adenocarcinoma Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cadonilimab Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Condition: Triple Negative Breast Neoplasms Interventions: Drug: Pembrolizumab injection; Drug: Capecitabine tablets; Radiation: Local radiotherapy Sponsor: UNICANCER Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer
Condition: Locally Advanced Unresectable Gastric Adenocarcinoma Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cadonilimab Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
